1. Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

2. Panelists

4. Dallas Heart Study: Lipid Characteristics of African Americans With Nonsense Mutations in PCSK9

5. ARIC: PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

7. SAR236553 Phase 2: Change in LDL-C at 4-Week Dosing Intervals on Atorvastatin

8. MENDEL: AMG 145 Phase 2 Monotherapy in Patients With Hypercholesterolemia

9. MENDEL: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

10. LAPLACE-TIMI 57: Phase 2 AMG 145 in Combination With Statin in Patients With Hypercholesterolemia

11. LAPLACE-TIMI 57: Study Design

12. LAPLACE-TIMI 57: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

13. LAPLACE-TIMI 57: Adverse Events

14. GAUSS: Phase 2 AMG 145 in Statin-Intolerant Patients

15. GAUSS: Baseline Characteristics

16. GAUSS: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

17. GAUSS: Percentage of Patients Achieving LDL-C Goals

18. SAR236553 in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe─Phase 2

19. SAR236553: Change in LDL-C in Patients With Heterozygous FH on Statin Therapy With or Without Ezetimibe

20. RUTHERFORD: Phase 2 AMG 145 in Patients With Heterozygous FH

21. RUTHERFORD: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

22. AMG 145: Ongoing Phase 2 Trials

23. SAR236553 on Top of Atorvastatin in Primary Hypercholesterolemia: Phase 2

24. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy: Phase 2 Studies

25. IV RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Doses Studied

26. Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy: Pooled Results

27. ODYSSEY Outcomes: Phase 3 Post-ACS With SAR236553

28. Program Summary

29. Thank you for participating in this activity.